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ABSTRACT
MicroRNAs are dysregulated in various cancers including colorectal cancer, and 
are potential useful biomarkers of disease development. We used next generation 
sequencing to investigate miRNA expression profiles in low- and high-grade 
intraepithelial dysplastic polyps from pigs carrying a mutation in the adenomatous 
polyposis coli tumour suppressor (APC1311, orthologous to human APC1309) that model 
an inherited predisposition to colorectal cancer, familial adenomatous polyposis. We 
identified several miRNAs and their isomiRs significantly (P < 0.05) differentially 
expressed between low and high-grade intraepithelial dysplastic polyps. Of these, 
ssc-let-7e, ssc-miR-98, ssc-miR-146a-5p, ssc-miR-146b, ssc-miR-183 and ssc-miR-
196a were expressed at higher level and ssc-miR-126-3p at lower level in high-grade 
intraepithelial dysplastic polyps. Functional miRNA target analysis revealed significant 
(P < 0.001) over-representation of cancer-related pathways, including ‘microRNAs in 
cancer’, ‘proteoglycans in cancer’, ’pathways in cancer’ and ‘colorectal cancer’. This 
is the first study to reveal miRNAs associated with premalignant transformation of 
colon polyps.
INTRODUCTION
MicroRNAs are short (~22nt) non-coding RNAs 
that are widely implicated in translational repression and 
degradation of target mRNAs, and estimated to down-
regulate up to 60% of genes [1]. They are emerging as 
predictive and prognostic biomarkers and as therapeutic 
targets in a wide range of human diseases, including 
cancer [2]. Cellular and circulating miRNAs have been 
linked to colorectal cancer (CRC), a common and severe 
form of cancer that often arises from adenomas (polyps) 
in the colon and rectum [3, 4].
Colorectal cancer is the third most commonly 
diagnosed cancer in males, second in females, and 
estimated to cause more than 600,000 deaths per year 
worldwide [5]. Lifestyle risk factors include smoking, 
physical inactivity, overweight, consumption of red and 
processed meat, and alcohol; but there is also a strong 
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2017
Oncotarget2www.impactjournals.com/oncotarget
genetic component to susceptibility [6, 7]. Development of 
strategies to prevent, diagnose and treat CRC will be aided 
by animals that model the disease and predict efficacy in 
humans.
The pig is increasingly recognised as a useful 
model species in translational medicine. Genetically 
modified pigs carrying oncogenic mutations similar to 
lesions responsible for human cancers could provide 
a valuable resource for preclinical studies [8]. We 
previously generated pigs carrying a germ line APC1311 
mutation, orthologous to human APC1309, to model 
familial adenomatous polyposis (FAP) [9]. FAP patients 
develop adenomatous polyps in the colon and rectum 
and are strongly predisposed to colorectal cancer [10, 
11]. APC1311 pigs develop dysplastic adenomas closely 
resembling early stage human FAP, and the progression of 
adenomatous polyps shows typical epithelial features of 
the adenoma-carcinoma sequence including aberrant crypt 
foci, adenomatous polyps with low (LG-IEN) and high-
grade intraepithelial (HG-IEN) dysplasia and carcinoma 
in situ [9]. More recently, we found that similar sets of 
protein-coding genes were involved in premalignant 
transformation in APC1311 pigs as in human CRC 
pathogenesis [12]. The aim of this study was to identify 
miRNAs associated with progression from low- to high-
grade intraepithelial dysplasia.
RESULTS AND DISCUSSION
Identification of differentially expressed miRNAs
To identify miRNAs associated with early stage 
adenoma progression, we performed miRNA profiling 
of normal colonic mucosa (NM), LG-IEN and HG-IEN 
samples using next generation sequencing. Cluster analysis 
revealed the most distinct expression patterns between 
LG-IEN and HG-IEN groups (Figure 1; Supplementary 
Figure 1). In total, more than 1200 small RNA sequences 
were analysed. Of these, only six miRNAs, including 
two isomiRs, showed differential expression (three up-, 
and three down-regulation) (P < 0.05) at the earliest stage 
of adenoma progression, i.e. between NM and LG-IEN 
samples (Supplementary Table 2). The expression level 
of another 44 miRNAs, including 26 isomiRs of known 
mature miRNAs, increased during progression from 
LG-IEN to HG-IEN (Supplementary Table 2). Between 
NM and HG-IEN samples we identified 41 differentially 
expressed miRNAs (21 up-regulated and 20 down-
regulated), including 31 isomiRs of known miRNAs 
(Supplementary Table 2).
Most (64%) differentially expressed miRNAs 
identified in our study were isomiRs (Supplementary Table 
2). These are variants of mature, canonical miRNAs that 
differ in sequence at the 3’ or 5’ ends, or harbour internal 
substitutions [13]. Most (77%) variations we identified 
involved the 3’ end, which is a common observation 
[14]. IsomiRs have been implicated in various biological 
pathways on the basis that their distribution differs 
consistently between cell types. For example, their 
expression profile differs between normal and cancer 
tissue and they may be used to discriminate various types 
of cancer [15]. Canonical miRNAs and their isomiRs 
are also known to act in co-ordination to target common 
molecular pathways [16]. We therefore performed a 
further analysis using a common identifier of the canonical 
miRNAs.
miRNA targets and pathway analysis
To determine possible biological roles of 
differentially expressed microRNAs in polyp 
development, we performed functional enrichment 
analysis based on their target mRNAs. Tools to predict 
porcine miRNA targets are not yet available, but porcine 
and human mature microRNA orthologues are highly 
conserved [17] enabling the use of human databases. 
MicroRNAs differentially expressed between NM and 
LG-IEN samples targeted 7743 genes. A total of 8339 
transcripts were targets of miRNAs up-regulated between 
LG-IEN and HG-IEN adenoma. Finally, 9794 genes were 
regulated by miRNAs differentially expressed between 
NM and HG-IEN samples (Supplementary Table 3). The 
pathways most significantly enriched (P ≤ 3.75 x 10-11) 
during early adenoma progression and targeted by the 
highest number of miRNAs were related to ‘microRNAs 
in cancer’, ‘proteoglycans in cancer’, ‘hepatitis B’ and 
‘cell cycle’ (Supplementary Table 4). Many other cancer-
related pathways were also significantly affected (P < 
0.001), including ‘viral carcinogenesis’, ’pathways in 
cancer’, ‘colorectal cancer’, ‘p53 signalling pathway’, 
and ‘transcriptional misregulation in cancer’. Interestingly, 
the involvement of multiple pathways related to cancer 
was observed even at the earliest stage of premalignant 
transformation i.e. during progression to LG-IEN, and 
of these the ‘microRNAs in cancer’ pathway was most 
significantly affected (P = 1.83 x 10-63) (Supplementary 
Table 4).
Validation of candidate miRNAs
Ten differentially expressed miRNAs were validated 
by qRT-PCR: ssc-let-7e, ssc-miR-98, ssc-miR-126-3p, 
ssc-miR-146a-5p, ssc-miR-146b, ssc-miR-155-5p, ssc-
miR-181b, ssc-miR-183, ssc-miR-191 and ssc-miR-196a. 
These were selected on the basis of ranking in the list of 
differentially expressed miRNAs and predicted functional 
relevance for CRC progression. In the more advanced 
HG-IEN samples, the levels of ssc-let-7e, ssc-miR-98, ssc-
miR-146a-5p, ssc-miR-146b, ssc-miR-183 and ssc-miR-
196a were significantly elevated compared to LG-IEN 
samples. In contrast, ssc-miR-126-3p was significantly 
reduced (Figure 2). Differences in ssc-miR-155-5p, ssc-
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miR-181b and ssc-miR-191 levels fell below statistical 
significance, but were still consistent with data from small 
RNA sequencing (Figure 2).
MicroRNAs can act to either promote or suppress 
tumorigenesis by regulating the expression of genes 
involved in angiogenesis, apoptosis, cell cycle control and 
differentiation. Members of the let-7 family are broadly 
considered to be tumour suppressors, downregulating 
several oncogenes including KRAS [18]. However, let-7e 
upregulation has been observed in human CRC tumours 
and associated with poor prognosis [19]. Interestingly, and 
consistent with the human data, we also found elevated 
levels of let-7e in HG-IEN. The microRNA miR-98 has 
been found to play a suppressive role in various human 
malignancies, but its role in CRC development is unclear. 
It has been recently reported that miR-98 was down-
regulated in colon cancer tissues compared to adjacent 
mucosa [20], but we found it significantly increased with 
precancerous adenoma development. We also found that 
ssc-miR-146a-5p and ssc-miR-146b were expressed at 
higher level in HG-IEN samples, which accords with 
findings in humans that these are expressed at higher 
levels in colon tumours than adjacent normal tissue, 
and are involved in CRC invasion [21, 22]. In our study 
Figure 1: Heatmap showing 44 differentially expressed mature miRNAs and isomiRs in low-grade intra-epithelial 
dysplasia (LG-IEN) and high-grade intra-epithelial dysplasia (HG-IEN) samples based on the normalised Log2-
transformed fold change values and the P-value.
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we detected upregulation of ssc-miR-183 in HG-IEN; 
similarly elevated levels of mir-183 is associated with 
human colorectal carcinogenesis [23, 24]. Finally, we 
found higher expression of ssc-miR-196a in HG-IEN; 
human miR-196a contributes to cell growth promotion, 
migration and invasion of colorectal cancer cells [25–
27]. We also found that ssc-miR-126 was expressed 
significantly less in HG- than in LG-IEN. Downregulation 
of miR-126 is observed during colon carcinogenesis in 
humans, and is associated with cancer cell proliferation, 
migration and invasion [28, 29].
Interestingly, a recently published comparison of 
human colon carcinomas with adjacent normal tissues 
showed a global up-regulation and a different set of 
miRNAs associated with carcinogenesis [30]. However, 
none of the eight miRNAs indicated in that study as 
potential diagnostic biomarkers and targets for CRC 
treatment showed differential expression in our samples. 
We also found only low and unchanged expression of the 
microRNAs, ssc-miR-155-5p, ssc-miR-181b and ssc-
miR-191, even though they have previously implicated 
in CRC development in humans [31–33]. It is likely that 
these differences reflect the earlier premalignant stage of 
disease development that we analysed, compared to the 
human data obtained from biopsies of later stages of CRC.
A study by Oberg et al. [34] of miRNAs expressed 
during the development of human sporadic and hereditary 
non-polyposis colorectal cancer (HNPCC) revealed more 
than 30 differentially expressed species. Their comparison 
of normal mucosa with adenoma showed involvement of 
the same miRNAs and a similar magnitude of difference 
as comparison of normal mucosa with later stage 
carcinoma [34], leading them to suggest that changes 
in miRNAs occur at an early stage persist during later 
stages of tumorigenesis in both proficient and defective 
DNA mismatch repair tumours. While our study revealed 
a few similarities with their study, several differentially 
expressed miRNAs such as miR-135a-1, miR-135a-2, 
miR135b showed no change in the FAP pigs. Where 
this discrepancy arises is unclear, but could be due to 
differences between HNPCC and FAP. As such, direct 
comparison of the porcine FAP model with early stage 
human adenomas would be informative.
We recently reported [12] that the use of whole 
biopsy samples of adenomas can introduce variability 
and reduce the sensitivity of differential transcriptome 
analysis as a result of cell heterogeneity, especially in 
the more advanced polyps. Laser-guided microdissection 
and collection of defined regions of adenoma avoided the 
obscuring effect of events in other tissue compartments 
and provided a more defined and sensitive analysis of 
adenoma progression. This effect is also likely to apply 
to the data presented here (Figure 1 and Supplementary 
Figure 1B). Although technically difficult at present, future 
analysis of microdissected adenoma would reduce such 
variability and probably reveal other miRNAs relevant to 
early adenoma progression.
In summary, we have detected several miRNAs (ssc-
let-7e, ssc-miR-98, ssc-miR-126-3p, ssc-miR-146a-5p, ssc-
miR-146b, ssc-miR-183 and ssc-miR-196a) associated with 
early-stage colorectal neoplasia in APC1311 pigs. Aberrant 
expression of these miRNAs can be considered as a molecular 
signature of precancerous progression in colorectal polyps, 
and they represent potential targets for early CRC therapy.
Figure 2: Relative miRNA expression in low-grade intra-epithelial dysplasia (LG-IEN) and high-grade intra-epithelial 
dysplasia (HG-IEN) samples. Values are means ± SD presented in relation to normal mucosa. *P < 0.05, **P < 0.01.
Oncotarget5www.impactjournals.com/oncotarget
MATERIALS AND METHODS
Ethics statement
All experimental procedures were conducted in 
accordance with the ethical standards, approved by the 
Government of Upper Bavaria (permit number 2 55.2-1-
54-2532-6-13) and performed according to the German 
Animal Welfare Act and European Union Normative for 
Care and Use of Experimental Animals (EU Directive 
2010/63/EU).
Animals and sample collection
APC1311/+ pigs were fed with normal pig diet. 
Polyp and normal mucosa samples were collected during 
colonoscopy examinations carried out approximately 
every 6 months, starting at 3 months old. Tissue samples 
were snap frozen in liquid nitrogen and stored at -80°C 
for subsequent analyses. For histopathology assessment, 
specimens were fixed in 4% buffered paraformaldehyde, 
embedded in paraffin, sectioned (3 μm) and stained with 
haematoxilin and eosin (H&E). Polyps were classified as 
LG-IEN (low grade intra epithelial dysplasia) or HG-IEN 
(high grade intra epithelial dysplasia) according to the 
AJCC TNM staging system [35].
Library preparation and NGS small RNA 
sequencing
Total RNA was purified using a Zymo Direct-zol 
RNA MiniPrep kit (Zymo Research). The quality and 
quantity of RNA samples was measured using an Agilent 
RNA 6000 Nano kit (Agilent) on a 2100 Bioanalyzer 
(Agilent) and a Nanodrop 2000 spectrophotomoter 
(Thermo Scientific). Libraries for small RNA sequencing 
were prepared (normal colon mucosa, NM, n=2; LG-IEN, 
n=5; HG-IEN, n=5) using 1 μg total RNA with TruSeq 
Small RNA Library Prep Kit (Illumina) according to the 
manufacturer’s instructions. Twelve samples were pooled 
and after validation (Agilent 2100 Bioanalyzer) run 
on MiSeq system (Illumina) using MiSeq Reagent Kits 
v2(Illumina) at 1x50 bp read configuration to generate 
FASTQ files.
Bioinformatic analysis of sequencing data
Analysis of Illumina sequence data was performed 
on a locally installed Galaxy server [36]. The first step 
was to detect and remove adapter sequences with the 
tool FastqMcf (Galaxy Version 1.0). The quality of Fastq 
files was checked before and after adapter clipping with 
FastQC (v0.11.2) and multiqc (Galaxy Version 0.6) to 
monitor performance of the processing step [37]. Since 
each resulting sequence should correspond to a small 
ncRNA, the data analysis strategy was to generate a 
count table for all unique sequences obtained as a basis 
for subsequent statistical analysis and to annotate and 
identify differentially expressed sequences. A series of 
standard Galaxy tools and additional converting tools from 
the ToolShed (https://toolshed.g2.bx.psu.edu/) were used. 
Initially, each adapter-clipped FastQ file was collapsed 
into the sequence and the number of appearances (using 
the tool “Collapse” - FastxTools http://hannonlab.cshl.edu/
fastx_toolkit/) ranked by the counts. The resulting FASTA 
files contained the counts and rank of the corresponding 
sequence in each header. FASTA files were then converted 
into Galaxy data file type with the tool “FASTA-to-
Tabular” (Version 1.1.0). The final count table containing 
only the sequences and the number of reads per sample 
was derived using an in-house tool named “Join datasets 
by identifier column” (https://toolshed.g2.bx.psu.edu/) 
and Galaxy (Version 1.0.2). This count table was filtered 
to remove sequences with negligible read counts (most 
likely sequencing artifacts), using 33 counts per million 
(CPM) per sample in at least two samples. This resulted in 
3214 sequences passing the filter. These sequences were 
then compared to all transcripts of Sus scrofa including 
non-coding RNAs and human and bovine sequences 
with NCBI BLAST+ [38]. The collection of BLAST 
databases contained precursor and mature microRNAs 
sequences from miRBase, sequences from NCBI and 
Ensembl, mostly non-coding RNAs but also protein-
coding transcripts, as well as tRNA and piRNA cluster 
sequences retrieved from NCBI. Porcine tRNA sequences 
were extracted from the genome sequence (Sus Scrofa 
10.2) using the GFF3 annotation file available at NCBI. 
All BLAST results were filtered and joined by removing 
duplicated hits. Sequences ranging from 19 to 24 nt 
assigned to miRNAs were used for analysis of differential 
expression with EdgeR [39]. IsomiRs were annotated 
based on the mature and step-loop miRNAs sequences 
deposited in miRBase v. 21, applying nomenclature 
proposed by Cloonan et al. [16].
MicroRNA target prediction and functional 
enrichment
MicroRNA target genes and KEGG (Kyoto 
Encyclopedia of Genes and Genomes) pathways 
influenced by differentially expressed miRNAs were 
predicted using DIANA-miRPath v3.0 software [40, 
41]. Experimentally validated human miRNA:mRNA 
interactions available in TarBase v.7.0 were applied. 
The resulting significance levels were adjusted for false 
discovery rate to take account of multiple testing.
Quantitative RT-PCR
To validate the small RNA sequencing results, forty 
RNA samples (NM, n=12; LG-IEN, n=24; HG-IEN, 
n=24) were reverse transcribed using a miScript II RT kit 
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(Qiagen). Quantification of 10 differentially expressed 
miRNAs was performed in triplicate by real-time PCR on 
an ABI 7500 thermocycler (Applied Biosystems) using 
a miScript SYBR Green PCR kit (Qiagen) according to 
the manufacturer’s recommendations. Primer specificity 
was verified by melting curve analysis. The sequence 
of custom-designed (www.qiagen.com/miDesign) PCR 
primers is shown in Supplementary Table 1. Relative 
expression level was calculated by the ΔΔCt method and 
miR-7-5p was used as a reference miRNA to normalise the 
results. The expression of miRNAs in LG-IEN and HG-
IEN were compared to normal mucosa. Students t test was 
used to compare LG-IEN and HG-IEN samples.
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